Container Top
Search

Events Calendar

EVENT SEARCH:

In This Section


Most Read Stories


Blogs:


Akron Docs in Haiti:
Almost home

First Bell - On Education:
Strange, sad story from Canton

Pets:
Happy St. Patrick's Day from Joey

The Heldenfiles:
NBC OK's New Non-Celebrity "Apprentice"

Akron Zips:
Akron vs. Green Bay — CBI preview

Tribe Matters:
Tribe claims infielder from Mets

Cleveland Browns:
Benard, Costanzo and Jennings resign with Browns

Balanced Ledger:
How times have changed?

Kent State Sports:
Tulsa @ Kent State – NIT preview

Cleveland Cavaliers:
Cavs Shift Start Time for Sunday Pistons Game

Buckeye Blogging:
Bucks High Seed – Turner High Praise

Varsity Letters:
Report: Boston College offers Smith

All Da King's Men:
ObamaCare To Reduce Premiums By 3000% ?

Blog of Mass Destruction:
Why Republicans Are Acting So Crazy

Akron Law Café:
Can Corporations Be Shamed?

Car Chase:
2010 CONCOURS SEASON IS UPON US

Let's Talk Real Estate:
A St Patty's Day Kiss!

Sound Check:
Willie Nelson & Family coming to the Akron Civic Theatre May 11

See Jane Style:
Who Wore What – The Oscars

HRLite House:
John Tesh Radio Show

Akron Gamer:
PlayStation's Move ups the interaction, fidelity

FDA says Prilosec can block benefits of Plavix

By Matthew Perrone
Associated Press

WASHINGTON: Federal health officials said today a popular heartburn medication can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.

The Food and Drug Administration said the stomach-soothing drug Prilosec cuts the blood-thinning effect of Plavix by half.

Regulators said the key ingredient in Procter & Gamble's Prilosec blocks Plavix, known generically as clopidogrel, from taking full effect.

''Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine,'' the agency said in a statement.

Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion last year, it's the world's second-best selling drug behind Pfizer's cholesterol drug Lipitor.

Because Plavix can upset the stomach, it is often prescribed with stomach acid-blocking drugs.

The FDA says patients who need to reduce their acid should take alternative drugs like Johnson & Johnson's Mylanta or Boehringer Ingelheim's Zantac.

Information about the drug interaction between Plavix and certain heartburn medications is not new. In January, Sanofi and Bristol-Myers updated Plavix's labeling to advise against using it in combination with certain heartburn drugs, following medical journal articles about the negative interaction.

A Sanofi spokeswoman said the company has now bolstered that labeling.

''We've strengthened the label to say that these drugs should be avoided altogether, not just discouraged,'' said Noelle Boyd, Sanofi's senior communications director.

WASHINGTON: Federal health officials said today a popular heartburn medication can interfere with the blood thinner Plavix, a drug taken by millions of Americans to reduce risks of heart attack and stroke.

The Food and Drug Administration said the stomach-soothing drug Prilosec cuts the blood-thinning effect of Plavix by half.

Regulators said the key ingredient in Procter & Gamble's Prilosec blocks Plavix, known generically as clopidogrel, from taking full effect.

''Patients at risk for heart attacks or strokes who use clopidogrel to prevent blood clots will not get the full effect of this medicine,'' the agency said in a statement.

Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb. With global sales of $8.6 billion last year, it's the world's second-best selling drug behind Pfizer's cholesterol drug Lipitor.

Because Plavix can upset the stomach, it is often prescribed with stomach acid-blocking drugs.

The FDA says patients who need to reduce their acid should take alternative drugs like Johnson & Johnson's Mylanta or Boehringer Ingelheim's Zantac.

Information about the drug interaction between Plavix and certain heartburn medications is not new. In January, Sanofi and Bristol-Myers updated Plavix's labeling to advise against using it in combination with certain heartburn drugs, following medical journal articles about the negative interaction.

A Sanofi spokeswoman said the company has now bolstered that labeling.

''We've strengthened the label to say that these drugs should be avoided altogether, not just discouraged,'' said Noelle Boyd, Sanofi's senior communications director.




Story tools

Email  Email   Print  Print   Save  Save   Reprint  Reprint   Popular  Most Popular   Reprint  Subscribe

Share this story

AddThis Social Bookmark Button














Most Commented Stories